Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC)- Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch- Partnership for trilaciclib in...
-
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
-
Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China G1 to receive $14 million upfront payment, sales royalties and...
-
RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
-
- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan RESEARCH TRIANGLE...
-
- Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements- G1 to retain full development and commercialization rights and book revenue for...
-
- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments- Genor to lead clinical development, regulatory submissions and commercialization of...
-
RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company has entered into a debt...
-
- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy - New Drug Application...
-
New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20Rintodestrant combination trial with palbociclib expected to initiate in 2Q20Management to host webcast...